TargeGen initiates Phase I clinical trial of topical AMD drug TG100801
TargeGen, Inc. has announced that the Company has initiated a single site Phase I clinical trial involving TG100801, a small molecule, topically applied multi-targeted kinase inhibitor for the treatment of macular degeneration and other debilitating diseases of the eye. Macular degeneration is the leading cause of blindness in adults. The trial, involving approximately 45 subjects, is expected to be completed by the end of the first quarter of 2007. The Company hopes to initiate Phase II studies with TG100801 in mid 2007.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.